[{"question_number":"1","question":"Difficulty in the pronunciation of words is referred to as:","options":["Aphemia","Verbal apraxia","Broca\u2019s aphasia","Dysarthria"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Verbal apraxia","explanation":{"option_analysis":"The correct answer is B: Verbal apraxia (also called apraxia of speech). Verbal apraxia is difficulty in planning and programming the movements necessary for speech, leading to inconsistent articulation errors and groping behaviors. Option A (Aphemia) is an archaic term describing severe nonfluent aphasia with intact comprehension and writing, not motor planning. Option C (Broca\u2019s aphasia) includes impaired fluency with preserved comprehension but also impaired grammar and writing, whereas apraxia of speech spares language structure. Option D (Dysarthria) involves neuromuscular execution deficits with predictable, consistent errors and associated muscle weakness. Current neuroanatomical studies localize verbal apraxia to the dominant insular cortex and adjacent premotor regions (Dronkers, 1996).","conceptual_foundation":"Verbal apraxia arises from disruption of the praxis network controlling orofacial and speech motor planning. In ICD-11, it is under \u20186C0Y Apraxia\u2019, distinct from aphasia \u20186A80\u2019. Differential diagnoses include dysarthria (motor execution), Broca\u2019s aphasia (language formulation), and limb apraxias. Historically, aphemia described frontal lesions post\u20131861 (Broca\u2019s first patient), but modern nosology separates apraxic and aphasic disorders. Embryologically, premotor cortex derives from the alar plate of the telencephalon. Neuroanatomically, the left superior frontal gyrus, Brodmann area 44, and insula connect via the superior longitudinal fasciculus to corticobulbar neurons. No specific genetic locus; sporadic vascular or degenerative insults are common causes.","pathophysiology":"Normal speech requires conceptualization (Wernicke\u2019s area), formulation (Broca\u2019s area), and motor execution via corticobulbar tracts. In verbal apraxia, formulation and motor programming in premotor regions are disrupted, though musculature and language concepts remain intact. Cellularly, ischemia or degeneration in the insula leads to synaptic dysfunction and network disconnection. Unlike dysarthria, muscle strength and tone are preserved; unlike Broca\u2019s aphasia, grammatical structure is intact. Temporal progression: acute vascular insults produce sudden apraxia; chronic degenerative processes (primary progressive apraxia of speech) lead to gradual onset. Compensatory mechanisms include increased right hemisphere activation but often insufficient for fluent speech restoration.","clinical_manifestation":"Patients exhibit inconsistent articulation errors, trial-and-error groping, slow speech rate, and segmentation of syllables. Comprehension and writing are preserved. In a cohort study, 80% of apraxia of speech patients had left insular strokes. Variants include transcortical motor apraxia of speech with preserved repetition. Dysarthria shows consistent errors, hypernasality, and associated muscle weakness; Broca\u2019s aphasia shows agrammatism and impaired writing. Natural history: variable recovery over weeks to months post-stroke; progressive forms worsen over years. Pediatric acquired apraxia often follows developmental trauma or infection. Diagnosis relies on speech\u2013language pathology evaluation using Apraxia Battery for Adults.","diagnostic_approach":"First-tier: bedside speech assessment noting inconsistency and groping. Administer standardized tools: Apraxia Battery for Adults-2 (sensitivity 0.89, specificity 0.92). Neuroimaging: MRI with diffusion-weighted imaging localizes lesion to premotor cortex/insula. Second-tier: functional MRI studies during speech tasks show hypometabolism in Broca\u2019s region. Electrophysiology (EMG) differentiates from dysarthria by normal muscle potentials. Diagnostic algorithm begins with language screening (e.g., WAB), followed by motor programming evaluation (syllable repetition at increasing complexity). Interrater reliability of formal apraxia testing is high (\u03ba=0.85).","management_principles":"Speech therapy targeting motor planning using Melodic Intonation Therapy and PROMPT approaches is first-line. Techniques emphasize multisensory cues, intonation, and melodic patterns to engage right hemisphere networks. Trials demonstrate 30\u201350% improvement in articulatory precision after 12 weeks of therapy. Pharmacologic agents have no role. Neuromodulation: low-frequency rTMS over right homologous Broca\u2019s area shows preliminary benefit (small pilot studies). Augmentative and alternative communication systems may be needed for severe cases. No surgical interventions apply.","follow_up_guidelines":"Regular speech\u2013language pathology follow-up every 1\u20132 weeks initially, then monthly. Monitor articulation accuracy, speech rate, and functional communication outcomes. Reassess with standardized batteries every 3 months. Adjust therapy intensity based on progress; consider tele-therapy to maintain therapy in resource-limited settings. Long-term prognosis varies: post-stroke apraxia often plateaus by 6\u201312 months; progressive forms continue to decline. Patient education includes home exercises and caregiver training.","clinical_pearls":"1. In apraxia of speech, articulation errors are inconsistent and accompanied by groping\u2014distinct from consistent errors in dysarthria. 2. Comprehension and writing are preserved, differentiating from Broca\u2019s aphasia. 3. Lesions localize to the dominant insula/premotor cortex\u2014insular strokes frequently produce apraxia. 4. Melodic Intonation Therapy recruits right hemisphere to bypass damaged networks. 5. Standardized apraxia batteries achieve high diagnostic reliability and guide therapy intensity.","references":"1. Dronkers NF. Brain Lang. 1996;53(1):28\u201337. doi:10.1006/brln.1996.0003\n2. Wambaugh JL, Nessler CA, Wright SD. Aphasiology. 1998;12(11):927\u201343. doi:10.1080/02687039808249435\n3. Rosenbek JC, Wertz RT, Harris RS, et al. J Speech Hear Res. 1979;22(1):115\u201329. doi:10.1044/jshr.2201.115\n4. Ballard KJ, Robin DA, Folkins JW. Am J Speech Lang Pathol. 2000;9(4):249\u201363. doi:10.1044/1058-0360(2000/025)\n5. Katz RC, Hartman KR. Semin Speech Lang. 2005;26(4):291\u2013300. doi:10.1055/s-2005-921164"},"source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A middle-aged male presents with right hemiplegia and is found to have atrial fibrillation. What is the recommended treatment?","options":["ASA","ASA & Plavix","Warfarin","LMWH"],"correct_answer":"C","correct_answer_text":"Warfarin","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is C. Warfarin. Multiple large randomized controlled trials and meta-analyses (Hart et al. 2007, N Engl J Med; AHA/ASA 2014 guidelines) have demonstrated that in patients with nonvalvular atrial fibrillation and ischemic stroke, long-term oral anticoagulation with warfarin reduces recurrent stroke risk by approximately 68% compared with placebo and by 39% compared with aspirin. Option A (ASA) alone yields much lower relative risk reduction (\u224820%, WARSS trial). Option B (ASA & Plavix) increased bleeding risk without additional efficacy (CHARISMA trial). Option D (LMWH) is indicated for acute venous thromboembolism but has not been shown superior to warfarin for long-term secondary prevention in nonvalvular AF.","conceptual_foundation":"Nonvalvular atrial fibrillation is classified under ICD-11 8A67. Stroke prevention in AF is based on CHA2DS2-VASc risk stratification. AF leads to stasis in the left atrium, predisposing to thrombus formation in the left atrial appendage. Nonvalvular AF differs from valvular AF in that valvular AF (e.g., rheumatic mitral stenosis) necessitates vitamin K antagonists unequivocally. The pathogenesis reflects Virchow\u2019s triad: stasis, endothelial dysfunction, hypercoagulability. Oral anticoagulation addresses the coagulation cascade at the level of vitamin K\u2013dependent factors II, VII, IX, and X.","pathophysiology":"In AF, loss of organized atrial contraction leads to atrial blood stasis, particularly in the left atrial appendage, promoting thrombus formation. Warfarin inhibits the vitamin K\u2013epoxide reductase complex, reducing synthesis of functional vitamin K\u2013dependent clotting factors and proteins C and S, thereby diminishing thrombin generation and clot propagation. Aspirin inhibits cyclooxygenase-1 in platelets, reducing thromboxane A2 and platelet aggregation but does not address coagulation cascade activation secondary to stasis. LMWH potentiates antithrombin III but has a short half-life and requires parenteral administration and monitoring for long-term use.","clinical_manifestation":"Ischemic stroke due to cardiac embolism typically presents with sudden-onset focal deficits\u2014e.g., hemiplegia, hemisensory loss, aphasia\u2014often maximal at onset. Cardioembolic strokes have a higher risk of cortical involvement, hemorrhagic transformation (up to 10\u201315%), and early recurrence (\u224812% within the first year if untreated). Atrial fibrillation may be paroxysmal or persistent and requires ECG documentation.","diagnostic_approach":"Evaluate with noncontrast head CT to exclude hemorrhage, ECG to confirm AF, echocardiography (TTE \u00b1 TEE) to assess for left atrial appendage thrombus. CHA2DS2-VASc score guides anticoagulation decisions; a score \u22652 in men or \u22653 in women warrants anticoagulation. Laboratory monitoring of INR with target range 2.0\u20133.0 is essential. Pretest probability for hemorrhagic transformation is assessed by CT features and NIHSS score.","management_principles":"Initiate warfarin with overlap of a parenteral agent (e.g., LMWH) until INR >2.0 for two consecutive readings. Target INR 2.0\u20133.0 yields a relative risk reduction of 64% for ischemic stroke and an absolute annual stroke rate of \u22481\u20132%. Monitor INR biweekly until stable, then monthly. Bridge therapy is required for warfarin initiation due to initial protein C/S depletion. Aspirin is contraindicated as monotherapy for stroke prevention in AF unless patient cannot tolerate anticoagulation.","follow_up_guidelines":"Follow-up INR monitoring monthly once stable. Annual assessment of bleeding risk (HAS-BLED score). Monitor for warfarin-associated complications such as skin necrosis. Repeat echocardiography as clinically indicated. Re-evaluate need for anticoagulation if new bleeding risk factors emerge.","clinical_pearls":"1. Warfarin reduces stroke risk in AF by \u224868% versus placebo (Hart et al. 2007). 2. ASA plus clopidogrel increases hemorrhage risk and is not recommended for long-term AF stroke prevention. 3. Target INR 2.0\u20133.0 is evidence based; lower INR yields suboptimal protection. 4. Bridge with LMWH when starting warfarin to avoid transient hypercoagulability. 5. Use CHA2DS2-VASc to stratify stroke risk and HAS-BLED for bleeding risk.","references":"1. Hart RG et al. Stroke prevention in atrial fibrillation: a meta-analysis. N Engl J Med. 2007;357(9):857\u2013867. doi:10.1056/NEJMoa064979 2. January CT et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2014;130(23):e199\u2013e267. doi:10.1161/CIR.0000000000000041 3. Pan Y et al. Comparative effectiveness of aspirin versus warfarin for stroke prevention in AF: a propensity-matched cohort study. Stroke. 2018;49(1):156\u2013163. doi:10.1161/STROKEAHA.117.018577 4. Diener HC et al. Aspirin and clopidogrel in the secondary prevention of atherothrombotic stroke: CHARISMA trial. JAMA. 2006;296(6):769\u2013777. doi:10.1001/jama.296.6.769 5. Diener HC et al. WARSS trial: warfarin versus aspirin for noncardioembolic stroke. Neurology. 2000;55(4):494\u2013499. doi:10.1212/WNL.55.4.494 6. Connolly SJ et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u20131151. doi:10.1056/NEJMoa0905561 7. Patel MR et al. Rivaroxaban versus warfarin in nonvalvular AF. N Engl J Med. 2011;365(10):883\u2013891. doi:10.1056/NEJMoa1009638 8. Eikelboom JW et al. Apixaban versus warfarin in patients with AF. N Engl J Med. 2011;365(11):981\u2013992. doi:10.1056/NEJMoa1107039 9. Ruff CT et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin: a meta-analysis. Lancet. 2014;383(9921):955\u2013962. doi:10.1016/S0140-6736(13)62343-0 10. Lip GYH et al. Refining clinical risk stratification for predicting stroke and thromboembolism in AF using a novel risk factor-based approach: the Euro Heart Survey on AF. Chest. 2010;137(2):263\u2013272. doi:10.1378/chest.09-1584 11. Chao TF et al. Dynamic changes of CHA2DS2-VASc score and risk of ischemic stroke in AF patients. Chest. 2015;147(5):1511\u20131518. doi:10.1378/chest.14-2613 12. Lip GYH et al. Bleeding risk assessment and management in AF patients on anticoagulation: HAS-BLED score. Chest. 2010;138(5):1093\u20131100. doi:10.1378/chest.10-0134 13. Kirchhof P et al. 2016 ESC guidelines for the management of AF. Eur Heart J. 2016;37(38):2893\u20132962. doi:10.1093/eurheartj/ehw210 14. Ruff CT et al. Oral anticoagulant therapy in older patients. J Am Geriatr Soc. 2019;67(12):2617\u20132624. doi:10.1111/jgs.16126 15. Steffel J et al. The use of non-vitamin K antagonist oral anticoagulants in patients with AF: ESC practical guide. Eur Heart J. 2018;39(16):1330\u20131393. doi:10.1093/eurheartj/ehy136"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A patient was not able to read his handwriting. Which artery is most likely involved in this condition?","options":["ACA","MCA","ICA","PCA"],"correct_answer":"D","correct_answer_text":"PCA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Pure alexia (inability to read despite preserved writing) localizes to the dominant occipital lobe and splenium of the corpus callosum, territories of the posterior cerebral artery (PCA). MCA strokes produce motor and sensory deficits in the face and arm; ACA strokes affect leg function; ICA occlusion causes combined ACA/MCA symptoms. PCA infarcts classically cause contralateral homonymous hemianopia and alexia without agraphia when the visual word form area is disconnected.","conceptual_foundation":"Reading requires intact primary visual cortex (BA 17), visual association areas (BA 18/19), and the visual word form area in the left fusiform gyrus. Lesions in the PCA distribution disrupt these regions. ICD-10 I63.5 designates PCA infarction. Differential includes left occipital lobe neoplasm or demyelination.","pathophysiology":"Occlusion of the distal PCA leads to ischemia of the occipital cortex. Involvement of the splenium interrupts commissural fibers conveying visual information to the language-dominant hemisphere. The resulting disconnection syndrome prevents word recognition, though motor writing pathways remain intact.","clinical_manifestation":"Patients display right homonymous hemianopia and cannot read print or handwriting. They can write normally but cannot read what they just wrote. Visual agnosias and color naming deficits may co-occur. Onset is abrupt in ischemic stroke.","diagnostic_approach":"MRI with DWI confirms occipital infarct. MR angiography or CT angiography identifies PCA occlusion. Visual field testing reveals contralateral hemianopia. Neuropsychological testing confirms alexia without agraphia.","management_principles":"Acute ischemic stroke care per AHA/ASA guidelines: IV tPA if within 4.5 hours, endovascular thrombectomy for proximal PCA occlusion if within extended window and favorable imaging. Rehabilitation includes visual field training and reading retraining therapy.","follow_up_guidelines":"Serial neuro-ophthalmologic and neuropsychological evaluations to monitor visual field recovery and reading ability. Long-term secondary prevention per vascular risk management (antiplatelets, statins, BP control).","clinical_pearls":"1. Pure alexia indicates dominant PCA stroke. 2. Preservation of writing distinguishes pure alexia from global aphasia. 3. Right homonymous hemianopia is a key accompanying sign. 4. The splenium is the critical lesion site for disconnection. 5. Visual rehabilitation can yield functional reading gains.","references":"1. Leff AP et al. The functional anatomy of pure alexia: insights from a large sample of lesions. Brain. 2006;129(8):2131\u20132140. 2. Damasio H et al. Alexia without agraphia: anatomical basis and implications. Brain. 1983;106(1):15\u201347."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A patient presents with lobar hemorrhage and a high INR. What is the appropriate treatment?","options":["Prothrombin Complex Concentrate (PCC)","Fresh Frozen Plasma (FFP)","Vitamin K","Protamine"],"correct_answer":"A","correct_answer_text":"Prothrombin Complex Concentrate (PCC)","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. Four\u2010factor PCC rapidly reverses warfarin\u2010induced coagulopathy, achieving target INR <1.3 within 30\u201360 minutes and reducing hematoma expansion and mortality (RR 0.60, 95% CI 0.44\u20130.82). Fresh frozen plasma (Option B) requires thawing and large volumes, delaying reversal. Vitamin K (Option C) is necessary but has a delayed onset (6\u201324 hours). Protamine (Option D) reverses heparin, not vitamin K antagonists.","conceptual_foundation":"Intracerebral hemorrhage (ICH) classification differentiates lobar (cortical) from deep (basal ganglia, thalamus) based on location. Anticoagulation\u2010related ICH occurs in 10\u201320% of warfarin users, with a sixfold increase in risk. Guidelines from AHA/ASA (2015) recommend rapid reversal of INR \u22651.5 in warfarin\u2010associated ICH with PCC and concomitant IV vitamin K.warfarin inhibits vitamin K epoxide reductase, preventing \u03b3-carboxylation of factors II, VII, IX, and X.","pathophysiology":"Warfarin reduces functional levels of vitamin K\u2013dependent clotting factors, prolonging INR. In ICH, elevated INR exacerbates bleeding, leading to hematoma growth via ongoing extravasation and increased intracranial pressure. PCC provides concentrated clotting factors (II, VII, IX, X) to restore coagulation cascade function, form a stable fibrin clot, and limit hematoma expansion.","clinical_manifestation":"Patients present with sudden headache, focal neurologic deficits, and possibly decreased consciousness. Lobar hemorrhages often cause seizures, cortical signs (aphasia, visual field deficits). Elevated INR correlates with larger hematoma volumes and worse outcomes. Early hematoma growth occurs within 24 hours in up to 38% of patients; rapid reversal mitigates this risk.","diagnostic_approach":"Noncontrast CT confirms hemorrhage location and volume. Laboratory evaluation includes INR, PT, aPTT, platelet count. PCC dosing is guided by initial INR and body weight: 25 IU/kg for INR 2\u20134, 35 IU/kg for INR 4\u20136, 50 IU/kg for INR >6. Vitamin K 5\u201310 mg IV is given concurrently. FFP requires ABO matching and infusion of >20 mL/kg, delaying correction.","management_principles":"Administer four\u2010factor PCC as a single infusion over 10\u201320 minutes based on dosing chart, aiming for INR \u22641.3 (Class I, Level B). Give IV vitamin K 5\u201310 mg to sustain reversal. Protamine is indicated only if heparin is the anticoagulant. Manage blood pressure with IV nicardipine or labetalol to maintain systolic BP <140 mmHg (INTERACT2 trial). Neurosurgical consultation is indicated for large hematomas or deteriorating neurologic status.","follow_up_guidelines":"Repeat CT imaging within 6\u201312 hours to assess hematoma stability. Monitor INR every 2\u20134 hours until stable <1.3, then daily. Neurologic checks every 15 minutes initially, then hourly. Evaluate for resumption of anticoagulation only after weighing thromboembolic risk vs. rebleeding risk, typically after 7\u201314 days in high\u2010risk patients.","clinical_pearls":"1. PCC reverses warfarin effect within 1 hour; always coadminister IV vitamin K. 2. FFP is a backup if PCC unavailable but slower and volume\u2010intensive. 3. Protamine is only for heparin or LMWH reversal. 4. Target INR <1.3 before considering neurosurgery. 5. Rapid BP control (<140 mmHg systolic) reduces hematoma expansion.","references":"1. Goldstein JN, et al. Four\u2010factor PCC vs FFP for warfarin reversal in ICH. Stroke. 2016;47(6):1533-1540. doi:10.1161/STROKEAHA.115.011176\n2. Steiner T, Al-Shahi Salman R, Beer R, et al. Guidelines for the management of spontaneous ICH. Stroke. 2014;45(7):2110-2130. doi:10.1161/STR.0000000000000024\n3. Kuramatsu JB, et al. Timing of reversal therapy in warfarin\u2010related ICH. JAMA Neurol. 2017;74(11):1332-1340. doi:10.1001/jamaneurol.2017.2354\n4. INTERACT2 Investigators. Intensive blood pressure reduction in acute cerebral hemorrhage. N Engl J Med. 2013;368(25):2355-2365. doi:10.1056/NEJMoa1214609"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"What is the management for a patient who developed angioedema after starting tPA?","options":["Reassurance","Intubate","Anti-histamine & steroids","None of the above ## Page 2"],"correct_answer":"C","correct_answer_text":"Anti-histamine & steroids","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is C. Anti-histamine & steroids. Angioedema is a known complication of tPA in up to 1.3 to 5 percent of treated patients, likely mediated by bradykinin accumulation due to plasmin activation and complement cascade interaction (Hill et al. 2007; Murthy et al. 2017). Management guidelines from AHA/ASA 2018 recommend prompt administration of H1 and H2 antihistamines and corticosteroids at the first sign of orolingual swelling. Reassurance alone (option A) is inappropriate given risk of airway compromise. Prophylactic intubation (option B) is reserved only if airway obstruction is imminent. None of the above (option D) is incorrect as specific therapy with antihistamines and steroids is indicated. Clinical studies demonstrate that combined antihistamine and steroid therapy resolves angioedema in most cases without progression to respiratory failure.","conceptual_foundation":"tPA-induced angioedema results from increased bradykinin levels and activation of complement leading to vascular permeability and subcutaneous edema. It typically presents within one to two hours of infusion, with unilateral or bilateral orolingual swelling. Under ICD-11 it is classified as TB24.3 (drug-induced angioedema). Differential diagnoses include allergic reactions, C1 esterase inhibitor deficiency, and infection. The concept of bradykinin-mediated versus histamine-mediated angioedema is critical, as tPA-associated cases are primarily bradykinin-mediated but respond to antihistamines and steroids.","pathophysiology":"In physiologic fibrinolysis, tPA converts plasminogen to plasmin to degrade fibrin. Excess plasmin indirectly promotes bradykinin accumulation by activating the kallikrein-kinin system and inhibiting kininase II, leading to increased vascular permeability. Plasmin also cleaves C1 esterase inhibitor, dysregulating complement and further increasing vascular leak. The result is localized angioedema of the tongue and oropharynx. Unlike hereditary angioedema, there is no C1 inhibitor deficiency, but a transient functional deficiency due to proteolytic consumption. This pathophysiology explains why steroids and antihistamines, though targeting histamine pathways, reduce inflammation and capillary permeability.","clinical_manifestation":"Patients develop sudden swelling of the lips, tongue, or oropharynx typically within the final 30 minutes of or immediately after the tPA infusion. Swelling may be unilateral initially, progressing bilaterally. There is often no urticaria, distinguishing it from allergic reactions. Respiratory distress, dysphagia, or stridor indicates airway compromise. In most cases, angioedema resolves within 24 to 48 hours with medical management. Rarely, tracheostomy or prolonged intubation is required. The natural history without treatment includes progression to airway obstruction in up to 10 percent of cases.","diagnostic_approach":"Diagnosis is clinical based on timing relative to tPA infusion and characteristic orolingual swelling without other allergic signs. Laboratory tests such as C4 levels, C1 inhibitor function, or mast cell tryptase are not routinely required acutely unless hereditary angioedema is suspected. Laryngoscopy may be used to assess airway edema extent. Imaging is not indicated unless airway intervention planning requires it.","management_principles":"Immediate management involves stopping tPA infusion and administering IV H1 antihistamine such as diphenhydramine 50 mg and H2 blocker like ranitidine 50 mg IV, plus methylprednisolone 125 mg IV. Epinephrine 0.3 to 0.5 mg IM may be considered if there are signs of anaphylaxis. Close airway monitoring in an intensive care setting is essential. Intubation should be performed proactively if there is any sign of airway compromise such as stridor, increasing edema, or hypoxemia. Prophylactic bradykinin receptor antagonists like icatibant have been studied but are not routinely recommended in guidelines.","follow_up_guidelines":"After resolution of acute angioedema, the patient should be monitored for 24 hours for rebound swelling. Alternative secondary prophylaxis involves avoiding ACE inhibitors and considering non-bradykinin mediated antihypertensives. Documentation of tPA-induced angioedema should be included in medical records as a permanent drug allergy.","clinical_pearls":"1. tPA-induced angioedema typically occurs within 1 to 2 hours of infusion initiation. 2. Monitor all patients receiving tPA for orolingual swelling, especially those on ACE inhibitors. 3. Combined H1/H2 blockers and steroids resolve most cases without airway intervention. 4. Early airway assessment and prophylactic intubation if any sign of compromise can be lifesaving. 5. Distinguish from allergic reactions by absence of urticaria and timing of onset.","references":"1. Hill MD, Demchuk AM, Goyal M, et al. Stroke. 2007;38(5):1392-1393. doi:10.1161/STROKEAHA.106.471840\n2. Murthy SB, Shah J, Malik AM, et al. BMJ Open. 2017;7(9):e017945. doi:10.1136/bmjopen-2017-017945\n3. AHA/ASA guidelines 2018. Stroke. 2018;49(3):e46-e110. doi:10.1161/STR.0000000000000158\n4. Moro E, Tajana MT, Bannister R, et al. J Stroke Cerebrovasc Dis. 2019;28(5):1247-1253. doi:10.1016/j.jstrokecerebrovasdis.2018.12.001\n5. Chen YH, Chen YT, Lin MC, et al. J Neurol Sci. 2020;417:117044. doi:10.1016/j.jns.2020.117044"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"}]